Moderna loses bid to invalidate vaccine delivery patents, teeing up potential infringement lawsuitnews2021-12-01T17:42:03+00:00December 1st, 2021|Fierce Pharma|
VBI Vaccines scores first FDA vaccine nod just as the hepatitis B market is set to expandnews2021-12-01T15:46:32+00:00December 1st, 2021|Fierce Pharma|
Get ready for M&A: Large biopharma companies will have $1.7T in dealmaking firepower next year, analyst saysnews2021-12-01T14:55:44+00:00December 1st, 2021|Fierce Pharma|
Amgen stalls Samsung’s Enbrel biosim until 2029 in 2nd patent win of the yearnews2021-12-01T13:40:36+00:00December 1st, 2021|Fierce Pharma|
Merck’s COVID-19 antiviral narrowly clears FDA panel—but committee echos support for revoking nod in favor of superior optionnews2021-11-30T23:37:32+00:00November 30th, 2021|Fierce Pharma|
Biogen takes another blow as appeal for Tecfidera patent revival falls shortnews2021-11-30T20:13:49+00:00November 30th, 2021|Fierce Pharma|
After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugsnews2021-11-30T19:14:14+00:00November 30th, 2021|Fierce Pharma|
GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision loomsnews2021-11-30T16:10:35+00:00November 30th, 2021|Fierce Pharma|
Bristol Myers Squibb’s next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutinynews2021-11-30T15:30:52+00:00November 30th, 2021|Fierce Pharma|
Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variantnews2021-11-30T14:57:03+00:00November 30th, 2021|Fierce Pharma|
